drugset / Trial / NCT06590961
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
NaSequentialOpen-labelTreatment
Summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Timeline
- Start
- 2025-02-20
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UBX-303061 | Unknown | — | Oral |